Changchun High-Tech (000661.SZ) subsidiary's voxviximab injection newly included in the national medical insurance catalog

Zhitong Finance APP news, Changchun High-Tech (000661.SZ) issued an announcement that Jinbeixin (generic name "Fuxinqibai Monoclonal Antibody Injection"), independently developed by the company's controlled subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has been newly included in the national medical insurance catalog. Jinbeixin (Fuxinqibai Monoclonal Antibody) is a novel fully human anti-IL-1 monoclonal antibody drug developed by Jinsai Pharmaceutical, belonging to Class 1 therapeutic biological products as a new drug. It can specifically bind to human IL-1 and block the production of inflammatory mediators induced by IL-1, and is used for adult patients with acute gouty arthritis attacks.